GTHX G1 Therapeutics Inc. Company Short-Term Debt

Public company logo of G1 Pharma (GTHX)

Serving as an assessment tool, the G1 Therapeutics, Inc. (GTHX) short-term liabilities chart helps illustrate an outsourcing model where production is delegated to external contractors to reduce costs. The current metric stands at 0.01, highlighting a liquidity deficit and a reliance on borrowed funds. Meanwhile, G1 Therapeutics, Inc. (GTHX) is implementing laboratory automation to accelerate testing without hiring additional scientists.

GTHX (G1 Therapeutics, Inc.) Company Short-Term Debts history from 07/04/2022 to 09/28/2024

Analytical breakdowns for G1 Therapeutics Inc. (GTHX)

- stock price and consensus target price:
Stock Price G1 Pharma|GTHX - Average Forecast Price
- market capitalization data:
Market Value G1 Therapeutics, Inc.|GTHX - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Book Value per Share G1 Therapeutics|GTHX - Book Capitalization|Market Value to Book Value Ratio g1therapeutics.com|GTHX - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio G1 Therapeutics, Inc.|GTHX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity G1 Pharma|GTHX - Company Cumulative Debt|Debt to Book Capitalization Ratio G1 Therapeutics, Inc.|GTHX - Company Long-Term Indebtedness|Company Short-Term Debts G1 Therapeutics|Quick Liquidity g1therapeutics.com
- net income and valuation multiples indicators:
GTHX - Company Net Income
Basic company analysis:GTHX - g1therapeutics.com
Flagship merchandise of G1 Pharma

G1 Therapeutics, Inc. (GTHX) dependence on a single drug amid the slow adoption of oncology treatments makes the company sensitive to liquidity. This indicator aggregates all financial obligations maturing within one year, allowing for an assessment of the risk of cash flow gaps in the event of declining revenue. Analyzing total short-term liabilities helps investors determine the business's ability to service its debts without raising emergency capital.

Direct competitors

Incyte - Company Short-Term Debts|Short-Term Debt Hutchison MediPharma|Nuvation Pharma (NUVB) - Company Short-Term Debt|Day One Biopharmaceuticals Inc - Company Short-Term Loans and Borrowings|MNPR (Monopar Therapeutics) - Company Short-Term Debts|Company Short-Term Debts inhibrx.com|Company Short-Term Debt I-Mab (IMAB)|Company Short-Term Debt FENC (Fennec Pharma)|Heron Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Loans and Borrowings NVCT|CHRS - Company Short-Term Debt|Short-Term Debt corbuspharma.com|cardiffoncology.com (CRDF) - Company Short-Term Debt|Company Short-Term Indebtedness BYSI|BCAB (BioAtla Inc) - Company Short-Term Debts|Company Current Liabilities Lixte Biotechnology, Inc. (LIXT)|Company Short-Term Debt Citius Pharmaceuticals (CTXR)|CLRB - Short-Term Debt|Company Short-Term Debt BioLineRx BLRX|Can-Fite BioPharma Ltd - Company Short-Term Debt|APRE - Company Short-Term Debt|Short-Term Debt Kazia Therapeutics|SLXN: Company Short-Term Debts|Short-Term Indebtedness NuCana NCNA|Company Current Liabilities CMRX|Short-Term Debt Cyclacel Pharmaceuticals, Inc. CYCC|Company Current Liabilities KRON (Kronos Bio Corp)|KTRA (Kintara Pharma) - Company Short-Term Loans and Borrowings|Oncternal Therapeutics - Company Current Liabilities|Amount of Current Liabilities PRTG (portagebiotech.com)